BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
Mar 05, 2007
 |  BioCentury  |  Strategy

Trans-Atlantic play

Backed by a $175 million infusion from investors, EUSA Pharma Inc. says last week's acquisition of specialty pharma company OPi S.A. will provide revenues, products and infrastructure that will serve as the European foundation for becoming a trans-Atlantic specialty pharma company with equally important U.S. and EU operations.

OPi (Lyon, France) was a good strategic fit for three primary reasons, according to Bryan Morton, president, CEO and founder of EUSA (King of Prussia, Penn.). "First, they have good products with rights in the EU and U.S.; second, they have good corporate structure that provides things like a supply chain, medical affairs and pharmacovigilance; and, third, they already had sales revenues."

Added benefits, he noted, were OPi's pipeline and R&D infrastructure.

OPi recorded 2006 sales of $23 million, up 69% over 2005, and was profitable. The...

Read the full 672 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >